433 related articles for article (PubMed ID: 33690666)
1. Discovery of novel candidates for anti-liposarcoma therapies by medium-scale high-throughput drug screening.
Grad I; Hanes R; Ayuda-Durán P; Kuijjer ML; Enserink JM; Meza-Zepeda LA; Myklebost O
PLoS One; 2021; 16(3):e0248140. PubMed ID: 33690666
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells.
Chauhan D; Tian Z; Zhou B; Kuhn D; Orlowski R; Raje N; Richardson P; Anderson KC
Clin Cancer Res; 2011 Aug; 17(16):5311-21. PubMed ID: 21724551
[TBL] [Abstract][Full Text] [Related]
3. Drug Repurposing Screen Identifies Novel Classes of Drugs with Anticancer Activity in Mantle Cell Lymphoma.
Han C; Yu X; Zhang C; Cai Y; Cao Y; Wang S; Shen J
Comb Chem High Throughput Screen; 2019; 22(7):483-495. PubMed ID: 31526347
[TBL] [Abstract][Full Text] [Related]
4. Systematic drug screening reveals specific vulnerabilities and co-resistance patterns in endocrine-resistant breast cancer.
Kangaspeska S; Hultsch S; Jaiswal A; Edgren H; Mpindi JP; Eldfors S; Brück O; Aittokallio T; Kallioniemi O
BMC Cancer; 2016 Jul; 16():378. PubMed ID: 27378269
[TBL] [Abstract][Full Text] [Related]
5. Kinase profiling of liposarcomas using RNAi and drug screening assays identified druggable targets.
Kanojia D; Garg M; Martinez J; M T A; Luty SB; Doan NB; Said JW; Forscher C; Tyner JW; Koeffler HP
J Hematol Oncol; 2017 Nov; 10(1):173. PubMed ID: 29132397
[TBL] [Abstract][Full Text] [Related]
6. Triptolide and Its Derivatives as Cancer Therapies.
Noel P; Von Hoff DD; Saluja AK; Velagapudi M; Borazanci E; Han H
Trends Pharmacol Sci; 2019 May; 40(5):327-341. PubMed ID: 30975442
[TBL] [Abstract][Full Text] [Related]
7. Antifungal application of nonantifungal drugs.
Stylianou M; Kulesskiy E; Lopes JP; Granlund M; Wennerberg K; Urban CF
Antimicrob Agents Chemother; 2014; 58(2):1055-62. PubMed ID: 24277040
[TBL] [Abstract][Full Text] [Related]
8. Investigational agent MLN9708/2238 targets tumor-suppressor miR33b in MM cells.
Tian Z; Zhao JJ; Tai YT; Amin SB; Hu Y; Berger AJ; Richardson P; Chauhan D; Anderson KC
Blood; 2012 Nov; 120(19):3958-67. PubMed ID: 22983447
[TBL] [Abstract][Full Text] [Related]
9. MLN2238, a proteasome inhibitor, induces caspase-dependent cell death, cell cycle arrest, and potentiates the cytotoxic activity of chemotherapy agents in rituximab-chemotherapy-sensitive or rituximab-chemotherapy-resistant B-cell lymphoma preclinical models.
Gu JJ; Hernandez-Ilizaliturri FJ; Mavis C; Czuczman NM; Deeb G; Gibbs J; Skitzki JJ; Patil R; Czuczman MS
Anticancer Drugs; 2013 Nov; 24(10):1030-8. PubMed ID: 23995855
[TBL] [Abstract][Full Text] [Related]
10. A preclinical study on the rescue of normal tissue by nicotinic acid in high-dose treatment with APO866, a specific nicotinamide phosphoribosyltransferase inhibitor.
Olesen UH; Thougaard AV; Jensen PB; Sehested M
Mol Cancer Ther; 2010 Jun; 9(6):1609-17. PubMed ID: 20515945
[TBL] [Abstract][Full Text] [Related]
11. High-throughput small molecule screen identifies inhibitors of aberrant chromatin accessibility.
Pattenden SG; Simon JM; Wali A; Jayakody CN; Troutman J; McFadden AW; Wooten J; Wood CC; Frye SV; Janzen WP; Davis IJ
Proc Natl Acad Sci U S A; 2016 Mar; 113(11):3018-23. PubMed ID: 26929321
[TBL] [Abstract][Full Text] [Related]
12. The evaluation of the anti-cancer activity of ixazomib on Caco2 colon solid tumor cells, comparison with bortezomib.
Engür S; Dikmen M
Acta Clin Belg; 2017 Dec; 72(6):391-398. PubMed ID: 28327055
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic assays for chemical biology and drug discovery.
Gul S
Clin Epigenetics; 2017; 9():41. PubMed ID: 28439316
[TBL] [Abstract][Full Text] [Related]
14. Mcl-1 downregulation by YM155 contributes to its synergistic anti-tumor activities with ABT-263.
Tang H; Shao H; Yu C; Hou J
Biochem Pharmacol; 2011 Nov; 82(9):1066-72. PubMed ID: 21784061
[TBL] [Abstract][Full Text] [Related]
15. A High-Content Screening of Anticancer Compounds Suggests the Multiple Tyrosine Kinase Inhibitor Ponatinib for Repurposing in Neuroblastoma Therapy.
Sidarovich V; De Mariano M; Aveic S; Pancher M; Adami V; Gatto P; Pizzini S; Pasini L; Croce M; Parodi F; Cimmino F; Avitabile M; Emionite L; Cilli M; Ferrini S; Pagano A; Capasso M; Quattrone A; Tonini GP; Longo L
Mol Cancer Ther; 2018 Jul; 17(7):1405-1415. PubMed ID: 29695637
[TBL] [Abstract][Full Text] [Related]
16. Action of YM155 on clear cell renal cell carcinoma does not depend on survivin expression levels.
Sim MY; Huynh H; Go ML; Yuen JSP
PLoS One; 2017; 12(6):e0178168. PubMed ID: 28582447
[TBL] [Abstract][Full Text] [Related]
17. Targeting abundant survivin expression in liposarcoma: subtype dependent therapy responses to YM155 treatment.
Vay C; Schlünder PM; Dizdar L; Esposito I; Ghadimi MPH; Knoefel WT; Krieg A
J Cancer Res Clin Oncol; 2022 Mar; 148(3):633-645. PubMed ID: 34860309
[TBL] [Abstract][Full Text] [Related]
18. Combinative effects of β-Lapachone and APO866 on pancreatic cancer cell death through reactive oxygen species production and PARP-1 activation.
Breton CS; Aubry D; Ginet V; Puyal J; Heulot M; Widmann C; Duchosal MA; Nahimana A
Biochimie; 2015 Sep; 116():141-53. PubMed ID: 26188110
[TBL] [Abstract][Full Text] [Related]
19. Selective Cytotoxicity of the NAMPT Inhibitor FK866 Toward Gastric Cancer Cells With Markers of the Epithelial-Mesenchymal Transition, Due to Loss of NAPRT.
Lee J; Kim H; Lee JE; Shin SJ; Oh S; Kwon G; Kim H; Choi YY; White MA; Paik S; Cheong JH; Kim HS
Gastroenterology; 2018 Sep; 155(3):799-814.e13. PubMed ID: 29775598
[TBL] [Abstract][Full Text] [Related]
20. Dual inhibition of HDAC and EGFR signaling with CUDC-101 induces potent suppression of tumor growth and metastasis in anaplastic thyroid cancer.
Zhang L; Zhang Y; Mehta A; Boufraqech M; Davis S; Wang J; Tian Z; Yu Z; Boxer MB; Kiefer JA; Copland JA; Smallridge RC; Li Z; Shen M; Kebebew E
Oncotarget; 2015 Apr; 6(11):9073-85. PubMed ID: 25940539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
